International Stem Cell Corp. (OTCMKTS:ISCO) Short Interest Up 24,410.3% in January

International Stem Cell Corp. (OTCMKTS:ISCO) was the target of a significant growth in short interest in January. As of January 30th, there was short interest totaling 9,559 shares, a growth of 24,410.3% from the January 15th total of 39 shares. Based on an average trading volume of 16,687 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.7% of the company’s stock are short sold. Currently, 0.7% of the company’s stock are short sold. Based on an average trading volume of 16,687 shares, the days-to-cover ratio is presently 0.6 days.

International Stem Cell Price Performance

International Stem Cell stock remained flat at $0.17 during trading hours on Tuesday. 15 shares of the company’s stock traded hands, compared to its average volume of 7,137. The stock has a 50-day simple moving average of $0.14 and a 200-day simple moving average of $0.14. The company has a market cap of $1.32 million, a PE ratio of -8.25 and a beta of 0.24. International Stem Cell has a twelve month low of $0.08 and a twelve month high of $0.27.

About International Stem Cell

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.